Clinical Paper

Deltex Medical Group PLC
25 April 2008


                            Deltex Medical Group plc


 American Society of Anesthesiologists clinical paper alerts its members to the
            value of oesophageal Doppler monitoring (ODM) in surgery


25 April 2008 - Deltex Medical Group plc ('Deltex Medical' or 'the Company'),
the UK's leading haemodynamic monitoring company, today notes the publication of
a clinical review paper on oesophageal Doppler-guided fluid management during
surgery in the monthly American Society of Anesthesiologists (ASA) communique to
its members.


The paper points out that:


   •traditional measures of fluid status and current strategies for fluid
    management may put the patient at significant risk of potentially harmful
    side-effects


   •much current practice in fluid therapy in the United States is guided by
    dogma and personal belief


   •there is a substantial evidence-base that demonstrates the value of
    flow-based (ODM) monitoring and management of fluid delivery during surgery


The authors also note that independent systematic reviews of the published data
('meta-analyses' and a US-government sponsored technology assessment) have
confirmed the value of ODM in the surgical setting.


Furthermore, the authors highlight that recent changes in reimbursement policy
in the United States mean that doctors are able to charge for the use of ODM to
guide fluid therapy during surgery or to assess haemodynamic status in
ventilated patients in intensive care.


The article was written by Professor Girish Joshi and Dr Ana Crawford both of
the University of Texas Southwestern Medical Center, Dallas and can be accessed
on-line at:


            www.asahq.org/Newsletters/2008/04-08/crawford04-08.html


Deltex Medical's Chief Executive, Andy Hill commented:

'The American Society of Anesthesiologists is respected as the leading 
association of anaesthetists in the USA and one 
of its primary goals is to set practice standards in anaesthesia and pain 
management.

'This paper brings the attention of the 42,000 practicing members of the ASA the 
key facts about the clinical value of ODM and alerts them to its new 
reimbursement status.'

For further information, please contact:-

Deltex Medical Group plc                         01243 774 837
Nigel Keen, Chairman                             [e-mail]
Andy Hill, Chief Executive                       [e-mail]
Ewan Phillips, Finance Director                  [e-mail]


Gavin Anderson & Company                         0207 554 1400
Deborah Walter                                   [e-mail]
Robert Speed                                     [e-mail]


Charles Stanley Securities                       020 7149 6000
(Nominated Adviser)
Philip Davies                                    [e-mail]
Russell Cook                                     [e-mail]


Notes for Editors

Deltex Medical manufactures and markets the CardioQ-ODM monitor, which uses
disposable ultra-sound probes inserted into the oesophagus to determine the
amount of blood being pumped around the body - 'circulating blood volume'.
Reduced circulating blood volume is known as hypovolaemia, which leads to
insufficient oxygen being delivered to the organs. This causes medical
complications including peripheral and major organ failure which can lead to
death. Hypovolaemia, which is akin to severe dehydration, affects virtually
every patient having surgery because of the combined effects of pre-operative
starvation, the impact of the anaesthetic agents and trauma from the surgery
itself. Using fluids and drugs, guided by the CardioQ-ODM, to optimise the
amount of circulating blood significantly reduces post-operative complications
allowing patients to make a faster, more complete recovery and return home
earlier.


The CardioQ-ODM incorporates the Company's proprietary software and a small
diameter, easy-to-use, minimally invasive, disposable oesophageal probe that is
used for transmitting and receiving an ultra-sound signal. By using this
technology, the CardioQ-ODM provides clinicians with the ability to
haemodynamically optimise critically ill patients and those undergoing routine
moderate to major surgery through the controlled administration of fluid and
drugs. Haemodynamic optimisation has been scientifically proven to improve the
speed and quality of patient recovery and reduce hospital stay.

There are already over 1,500 CardioQ-ODMs currently in use in hospitals
worldwide and distribution arrangements are in place in over 30 countries. In
addition, there are currently more than 100 clinical publications on the use of
the CardioQ-ODM which have repeatedly:-


   •Validated the results of the Monitor against known standards for
    measuring cardiac output, demonstrating that the technology works


   •Proved that the CardioQ-ODM works in a wide range of surgical procedures


   •Demonstrated that the Company's technology provides significant health
    and economic benefits by helping to reduce post-operative complications and
    length of hospital stays by an average of 30 to 40 per cent for a wide range
    of patients.


The SupraQ is an entirely non-invasive device which uses an ultrasound probe
held at the base of the patient's neck to track the flow of blood in the aorta;
it presents the same data as the CardioQ-ODM in a similar format and is used for
taking snapshots or monitoring over short periods.



                      This information is provided by RNS
            The company news service from the London Stock Exchange